Kymera Therapeutics, Inc. KYMR
111.95
(3.86)
(3.33%)
as of 25 Sep
- Market cap
- $9.7B
- P/E
- 0.0×
Follow KYMR
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (24.15%) | (27.09%) | (25.78%) | (32.09%) |
+8 more TTM periods Free account |
|
| (21.58%) | (24.35%) | (22.89%) | (27.62%) | ||
ROIC |
(26.72%) | (25.22%) | (29.80%) | (46.94%) | |
Return on Tangible Assets |
(42.44%) | (47.99%) | (37.46%) | (58.81%) | |
Average Days of Receivables |
69.52 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.42) | (2.50) | (2.77) | (2.64) | |
Free Cash Flow |
(237.96) | (244.00) | (234.34) | (230.21) | |
Capital Expenditures |
(1.19) | (1.42) | (1.45) | (2.28) | |
Piotroski F-Score |
5.00 | 4.00 | 4.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(10.76%) | (11.07%) | (9.59%) | (15.68%) | |
Accounts Receivable Turnover |
8.71 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
357.68% | 649.77% | 807.34% | 696.38% | |
Selling, General and Administrative Expense of Revenue |
72.15% | 140.40% | 173.90% | 154.53% | |
Share Based Compensation of Revenue |
62.10% | 119.82% | 152.77% | 135.48% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 0.77 | 0.75 | 0.77 | |
Depreciation/Fixed assets |
(0.03) | (0.02) | (0.01) | (0.04) | |
Capex/Depreciation |
1.13 | 1.78 | 2.56 | 1.24 | |
Revenue per Share |
1.07 | 0.53 | 0.46 | 0.50 | |
Operating CF per Share |
(2.41) | (2.49) | (2.76) | (2.61) | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.03) | |
Capex to Sales |
0.01 | 0.03 | 0.04 | 0.05 | |
Net Profit Margin |
(285.33%) | (611.94%) | (794.04%) | (674.81%) |
Columns are period end dates